- Home
- UMAC vs OBIO Comparison
UMAC vs OBIO Comparison
Compare UMAC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- OBIO
- Stock Information
- Founded
- UMAC 2019
- OBIO 2017
- Country
- UMAC United States
- OBIO United States
- Employees
- UMAC N/A
- OBIO N/A
- Industry
- UMAC
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- UMAC
- OBIO Health Care
- Exchange
- UMAC Nasdaq
- OBIO Nasdaq
- Market Cap
- UMAC 165.6M
- OBIO 156.6M
- IPO Year
- UMAC 2024
- OBIO N/A
- Fundamental
- Price
- UMAC $12.95
- OBIO $5.28
- Analyst Decision
- UMAC Strong Buy
- OBIO Strong Buy
- Analyst Count
- UMAC 2
- OBIO 5
- Target Price
- UMAC $11.00
- OBIO $15.80
- AVG Volume (30 Days)
- UMAC 3.4M
- OBIO 182.8K
- Earning Date
- UMAC 02-20-2025
- OBIO 11-12-2024
- Dividend Yield
- UMAC N/A
- OBIO N/A
- EPS Growth
- UMAC N/A
- OBIO N/A
- EPS
- UMAC N/A
- OBIO N/A
- Revenue
- UMAC $3,561,303.00
- OBIO $2,647,000.00
- Revenue This Year
- UMAC N/A
- OBIO $22.61
- Revenue Next Year
- UMAC $66.18
- OBIO $16.64
- P/E Ratio
- UMAC N/A
- OBIO N/A
- Revenue Growth
- UMAC N/A
- OBIO N/A
- 52 Week Low
- UMAC $0.98
- OBIO $3.96
- 52 Week High
- UMAC $23.62
- OBIO $10.06
- Technical
- Relative Strength Index (RSI)
- UMAC 50.74
- OBIO 50.69
- Support Level
- UMAC $12.27
- OBIO $5.00
- Resistance Level
- UMAC $13.97
- OBIO $5.70
- Average True Range (ATR)
- UMAC 2.29
- OBIO 0.57
- MACD
- UMAC -0.63
- OBIO 0.05
- Stochastic Oscillator
- UMAC 19.81
- OBIO 56.41
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is a development stage technology company.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.